Passage BIO Inc
For the period ended Dec 31, 2023. Filed Mar 4, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 4, 2024
PASG$3.43-13.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, | ||||||
| (in thousands, except share and per share data) · · 2023 · · 2022 | ||||||
| Assets · · · · | ||||||
| Current assets: · · · · | ||||||
| Cash and cash equivalents | | $21,709 | | $34,601 | ||
| Marketable securities | | | 92,585 | | | 155,009 |
| Prepaid expenses and other current assets | | 923 | | 926 | ||
| Prepaid research and development | | 2,742 | | 6,508 | ||
| Total current assets | | 117,959 | | 197,044 | ||
| Property and equipment, net | | 15,295 | | 22,515 | ||
| Right of use assets - operating leases | | | 16,858 | | 19,723 | |
| Other assets | | 433 | | 4,267 | ||
| Total assets | | $150,545 | | $243,549 | ||
| Liabilities and stockholders’ equity | | | | | ||
| Current liabilities: | | | | | ||
| Accounts payable | | $1,298 | | $4,065 | ||
| Accrued expenses and other current liabilities | | 11,670 | | 11,011 | ||
| Operating lease liabilities | | | 3,373 | | 3,275 | |
| Total current liabilities | | 16,341 | | 18,351 | ||
| Operating lease liabilities - noncurrent | | 22,921 | | 23,832 | ||
| Total liabilities | | 39,262 | | 42,183 | ||
| | | | | | | |
| Commitments and contingencies (note 10) | | | | | ||
| | | | | | | |
| Stockholders’ equity: | | | | | ||
| Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding at both December 31, 2023 and December 31, 2022 | | | — | | | — |
| Common stock, $0.0001 par value: 300,000,000 shares authorized; 54,944,130 shares issued and outstanding at December 31, 2023 and 54,614,690 shares issued and outstanding at December 31, 2022 | | 5 | | 5 | ||
| Additional paid‑in capital | | 705,789 | | 694,733 | ||
| Accumulated other comprehensive income (loss) | | | (43) | | | (966) |
| Accumulated deficit | | (594,468) | | (492,406) | ||
| Total stockholders’ equity | | 111,283 | | 201,366 | ||
| Total liabilities and stockholders’ equity | | $150,545 | | $243,549 | ||
Passage Bio, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.